

Dennis A Revicki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/851750/publications.pdf>

Version: 2024-02-01

41
papers

8,311
citations

304743

22
h-index

315739

38
g-index

41
all docs

41
docs citations

41
times ranked

11686
citing authors

#	ARTICLE	IF	CITATIONS
1	Psychometric Properties of the Asthma Symptom Index in Patients with Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 400-409.e1.	3.8	2
2	Evaluating response in gastroparesis: Patient reported outcome measures and survey instruments. , 2021, , 451-460.		0
3	A Scoring Algorithm for Deriving Utility Values from the Neuro-QoL for Patients with Multiple Sclerosis. <i>Medical Decision Making</i> , 2020, 40, 897-911.	2.4	5
4	Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 82.	1.9	3
5	Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 174.	2.7	10
6	Evaluating minimal important differences and responder definitions for the asthma symptom diary in patients with moderate to severe asthma. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 22.	1.9	11
7	A Scale to Assess Activities of Daily Living in Pantothenate Kinase-Associated Neurodegeneration. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 139-149.	1.5	9
8	The American neurogastroenterology and motility society gastroparesis cardinal symptom index-daily diary (ANMS GCSI-DD): Psychometric evaluation in patients with idiopathic or diabetic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13553.	3.0	14
9	The content validity of the ANMS GCSI-DD in patients with idiopathic or diabetic gastroparesis. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 61.	1.9	12
10	Estimation of a Preference-Based Summary Score for the Patient-Reported Outcomes Measurement Information System: The PROMIS-Preference (PROPr) Scoring System. <i>Medical Decision Making</i> , 2018, 38, 683-698.	2.4	92
11	Cross-sectional validation of the PROMIS-Preference scoring system. <i>PLoS ONE</i> , 2018, 13, e0201093.	2.5	46
12	Evaluation of options for presenting health-states from PROMIS® item banks for valuation exercises. <i>Quality of Life Research</i> , 2018, 27, 1835-1843.	3.1	14
13	Editorial Comment: "Quantifying Barriers to Improvement of Treatment Satisfaction in Men With Erectile Dysfunction: Use of Person-Item Maps". <i>Journal of Sexual Medicine</i> , 2017, 14, 160-161.	0.6	0
14	Selection of key health domains from PROMIS® for a generic preference-based scoring system. <i>Quality of Life Research</i> , 2017, 26, 3377-3385.	3.1	39
15	Using Linear Equating to Map PROMIS® Global Health Items and the PROMIS-29V2.0 Profile Measure to the Health Utilities Index Mark3. <i>Pharmacoeconomics</i> , 2016, 34, 1015-1022.	3.3	45
16	Assessing the Reliability and Validity of the Sheehan Irritability Scale in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1080-1086.	2.2	6
17	The PROMIS of QALYs. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 122.	2.4	44
18	Adolescent body weight and health-related quality of life rated by adolescents and parents: the issue of measurement bias. <i>BMC Public Health</i> , 2015, 15, 1192.	2.9	15

#	ARTICLE	IF	CITATIONS
19	Reliability and Validity of the Work Instability Scale for Rheumatoid Arthritis. <i>Value in Health</i> , 2015, 18, 1008-1015.	0.3	12
20	The Impact of Medication on Health-Related Quality of Life in Patients with Generalized Anxiety Disorder. <i>CNS Drugs</i> , 2015, 29, 29-40.	5.9	8
21	Introduction to special section: quantitative methods. <i>Quality of Life Research</i> , 2015, 24, 1-3.	3.1	15
22	US Valuation of Health Outcomes Measured Using the PROMIS-29. <i>Value in Health</i> , 2014, 17, 846-853.	0.3	117
23	The case for an international patient-reported outcomes measurement information system (PROMIS®) initiative. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 210.	2.4	127
24	Asthma Symptom Utility Index: Reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 1078-1084.	2.9	41
25	Humanistic and economic burden of generalized anxiety disorder in North America and Europe. <i>Journal of Affective Disorders</i> , 2012, 140, 103-112.	4.1	117
26	Differential Item Functioning in Quality of Life Measure between Children with and without Special Health-Care Needs. <i>Value in Health</i> , 2011, 14, 872-883.	0.3	20
27	Content Validity of the Female Sexual Function Index (FSFI) in Pre- and Postmenopausal Women with Hypoactive Sexual Desire Disorder. <i>Journal of Sexual Medicine</i> , 2011, 8, 2237-2245.	0.6	42
28	Understanding the relationships between health outcomes in generalized anxiety disorder clinical trials. <i>Quality of Life Research</i> , 2011, 20, 255-262.	3.1	8
29	The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 1179-1194.	5.0	3,521
30	Predicting EuroQol (EQ-5D) scores from the patient-reported outcomes measurement information system (PROMIS) global items and domain item banks in a United States sample. <i>Quality of Life Research</i> , 2009, 18, 783-791.	3.1	129
31	Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. <i>Quality of Life Research</i> , 2009, 18, 873-880.	3.1	1,272
32	Agreement was not found in adolescents'™ quality of life rated by parents and adolescents. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 337-346.	5.0	38
33	Assessing health-related quality of life in generalized anxiety disorder using the Quality Of Life Enjoyment and Satisfaction Questionnaire. <i>International Clinical Psychopharmacology</i> , 2009, 24, 289-295.	1.7	40
34	Health-related quality of life and utilities in primary-care patients with generalized anxiety disorder. <i>Quality of Life Research</i> , 2008, 17, 1285-1294.	3.1	51
35	Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. <i>Journal of Clinical Epidemiology</i> , 2008, 61, 102-109.	5.0	1,701
36	Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. <i>Journal of Rheumatology</i> , 2008, 35, 206-15.	2.0	43

#	ARTICLE	IF	CITATIONS
37	Clinical Assessment of Asthma Symptom Control: Review of Current Assessment Instruments. Journal of Asthma, 2006, 43, 481-487.	1.7	33
38	Gastroparesis Cardinal Symptom Index (GCSI): Development and validation of a patient reported assessment of severity of gastroparesis symptoms. Quality of Life Research, 2004, 13, 833-844.	3.1	311
39	Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders. Clinical Gastroenterology and Hepatology, 2004, 2, 769-777.	4.4	79
40	Integrating Patient Preferences Into Health Outcomes Assessment. Chest, 1998, 114, 998-1007.	0.8	215
41	The Measurement of Health-Related Quality of Life in a Population with Generalized Anxiety Disorder – Findings from the QUEST Study. , 0, , .		4